<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">nogr</journal-id><journal-title-group><journal-title xml:lang="ru">Экспериментальная и клиническая гастроэнтерология</journal-title><trans-title-group xml:lang="en"><trans-title>Experimental and Clinical Gastroenterology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1682-8658</issn><publisher><publisher-name>«Global Media Technologies»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.31146/1682-8658-ecg-211-3-41-45</article-id><article-id custom-type="elpub" pub-id-type="custom">nogr-2333</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКАЯ ГАСТРОЭНТЕРОЛОГИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL GASTROENTEROLOGY</subject></subj-group></article-categories><title-group><article-title>Комбинированная терапия гастроэзофагеальной рефлюксной болезни при коморбидности с функциональной диспепсией</article-title><trans-title-group xml:lang="en"><trans-title>Combined therapy of gastroesophageal reflux disease in comorbidity with functional dyspepsia</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Каримов</surname><given-names>М. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Karimov</surname><given-names>M. M.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Зуфаров</surname><given-names>П. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Zufarov</surname><given-names>P. S.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Собирова</surname><given-names>Г. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Sobirova</surname><given-names>G. N.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Каримова</surname><given-names>Д. К.</given-names></name><name name-style="western" xml:lang="en"><surname>Karimova</surname><given-names>D. K.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Хайруллаева</surname><given-names>С. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Khairullaeva</surname><given-names>S. S.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Республиканский специализированный научно-практический медицинский центр терапии и медицинской реабилитации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>The Republican Specialized Scientific and Practical Medical Center for Therapy and Medical Rehabilitation</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>25</day><month>07</month><year>2023</year></pub-date><volume>0</volume><issue>3</issue><fpage>41</fpage><lpage>45</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Каримов М.М., Зуфаров П.С., Собирова Г.Н., Каримова Д.К., Хайруллаева С.С., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Каримов М.М., Зуфаров П.С., Собирова Г.Н., Каримова Д.К., Хайруллаева С.С.</copyright-holder><copyright-holder xml:lang="en">Karimov M.M., Zufarov P.S., Sobirova G.N., Karimova D.K., Khairullaeva S.S.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.nogr.org/jour/article/view/2333">https://www.nogr.org/jour/article/view/2333</self-uri><abstract><p>Комбинироваанное использование ингибиторов протонной помпы и прокинетиков при фармакотерапии ГЭРБ и ФД приводит к снижению изжоги и боли за грудиной. Однако, такие симптомы, как регургидация, отрыжка, чувство раннего насыщения и тяжесть после еды купировались неэффективно. Включение в комплекс лечения прокинетика домперидона в дозе 10 мг 3 раза в день способствовало более эффективной регрессии симптомов нарушения моторики пищевода и желудка.</p></abstract><trans-abstract xml:lang="en"><p>It has been shown that in patients with GERD and functional dyspepsia, the use of proton pump inhibitors leads to a decrease in heartburn and pain behind the sternum. However, symptoms such as regurgitation, belching, feeling of early satiety and heaviness after eating were stopped ineffectively. The inclusion in the treatment complex of the prokinetic domperidone at a dose of 10 mg 3 times a day contributed to a more effective regression of symptoms of impaired motility of the esophagus and stomach.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>гастроэзофагеальная рефлюксная болезнь</kwd><kwd>функциональная диспепсия</kwd><kwd>ингибиторы протонной помпы</kwd><kwd>прокинетики</kwd></kwd-group><kwd-group xml:lang="en"><kwd>gastroesophageal reflux disease</kwd><kwd>functional dyspepsia</kwd><kwd>proton pump inhibitors</kwd><kwd>prokinetics</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">de Bortoli N., Martinucci I., Bellini M., Savarino E., Savarino V., Blandizzi C., Marchi S. Overlap of functional heartburn and gastroesophageal reflux disease with irritable bowel syndrome. World J Gastroenterol. 2013 Sep 21;19(35):5787-97. doi: 10.3748/wjg.v19.i35.5787.</mixed-citation><mixed-citation xml:lang="en">de Bortoli N., Martinucci I., Bellini M., Savarino E., Savarino V., Blandizzi C., Marchi S. Overlap of functional heartburn and gastroesophageal reflux disease with irritable bowel syndrome. World J Gastroenterol. 2013 Sep 21;19(35):5787-97. doi: 10.3748/wjg.v19.i35.5787.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Domperidone IND Packet US Food and Drug Administration. 2018. 17 p. Available at: https: //www.fda.gov/downloads/drugs/development_approval_process/how_drugs_are_developed_and_approved/appro Access 05.05.2021.</mixed-citation><mixed-citation xml:lang="en">Domperidone IND Packet US Food and Drug Administration. 2018. 17 p. Available at: https: //www.fda.gov/downloads/drugs/development_approval_process/how_drugs_are_developed_and_approved/appro Access 05.05.2021.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Drossman D. Rome III: The functional gastrointestinal disorders. 3rd ed. McLean, VA: Degnon Associates, Inc., 2006, pp. 369-418.</mixed-citation><mixed-citation xml:lang="en">Drossman D. Rome III: The functional gastrointestinal disorders. 3rd ed. McLean, VA: Degnon Associates, Inc., 2006, pp. 369-418.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Keohane J., Quigley E. M. Functional dyspepsia and nonerosive reflux disease: clinical interactions and their implications. MedGenMed. 2007 Aug 8;9(3):31. PMID: 18092037</mixed-citation><mixed-citation xml:lang="en">Keohane J., Quigley E. M. Functional dyspepsia and nonerosive reflux disease: clinical interactions and their implications. MedGenMed. 2007 Aug 8;9(3):31. PMID: 18092037</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Ortiz A., Cooper C. J., Alvarez A., Gomez Y., Sarosiek I., McCallum R. W. Cardiovascular safety profile and clinical experience with high-dose domperidone therapy for nausea and vomiting. Am J Med Sci. 2015 May;349(5):421-4. doi: 10.1097/MAJ.0000000000000439.</mixed-citation><mixed-citation xml:lang="en">Ortiz A., Cooper C. J., Alvarez A., Gomez Y., Sarosiek I., McCallum R. W. Cardiovascular safety profile and clinical experience with high-dose domperidone therapy for nausea and vomiting. Am J Med Sci. 2015 May;349(5):421-4. doi: 10.1097/MAJ.0000000000000439.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Parkman H.P., Jacobs M. R., Mishra A., Hurdle J. A., Sachdeva P., Gaughan J. P., Krynetskiy E. Domperidone treatment for gastroparesis: demographic and pharmacogenetic characterization of clinical efficacy and side-effects. Dig Dis Sci. 2011 Jan;56(1):115-24. doi: 10.1007/s10620-010-1472-2.</mixed-citation><mixed-citation xml:lang="en">Parkman H.P., Jacobs M. R., Mishra A., Hurdle J. A., Sachdeva P., Gaughan J. P., Krynetskiy E. Domperidone treatment for gastroparesis: demographic and pharmacogenetic characterization of clinical efficacy and side-effects. Dig Dis Sci. 2011 Jan;56(1):115-24. doi: 10.1007/s10620-010-1472-2.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Schey R., Saadi M., Midani D., Roberts A. C., Parupalli R., Parkman H. P. Domperidone to Treat Symptoms of Gastroparesis: Benefits and Side Effects from a Large Single-Center Cohort. Dig Dis Sci. 2016 Dec;61(12):3545-3551. doi: 10.1007/s10620-016-4272-5.</mixed-citation><mixed-citation xml:lang="en">Schey R., Saadi M., Midani D., Roberts A. C., Parupalli R., Parkman H. P. Domperidone to Treat Symptoms of Gastroparesis: Benefits and Side Effects from a Large Single-Center Cohort. Dig Dis Sci. 2016 Dec;61(12):3545-3551. doi: 10.1007/s10620-016-4272-5.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Wolfe M.M., Lowe R. C. Investing in the Future of GERD. J. Clin. Gastroenterol. 2007;41(Supplement 2): S209-S216. doi: 10.1097/MCG.0b013e318032390f</mixed-citation><mixed-citation xml:lang="en">Wolfe M.M., Lowe R. C. Investing in the Future of GERD. J. Clin. Gastroenterol. 2007;41(Supplement 2): S209-S216. doi: 10.1097/MCG.0b013e318032390f</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Yuan Y., Hunt R. H.Intragastric acid suppressing effect of proton pump inhibitors twice daily at steady state in healthy volunteers: evidence of an unmet need? Am. J. Gastroenterol. 2008;103 (suppl 1): S50-S51. doi: 10.14309/00000434-200809001-00128.</mixed-citation><mixed-citation xml:lang="en">Yuan Y., Hunt R. H.Intragastric acid suppressing effect of proton pump inhibitors twice daily at steady state in healthy volunteers: evidence of an unmet need? Am. J. Gastroenterol. 2008;103 (suppl 1): S50-S51. doi: 10.14309/00000434-200809001-00128.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
